More than half of the patients planned for the clinical study have already been enrolled, with the trial progressing rapidly through dose escalation Advancement of ONA-255 marks an important milestone following Ona’s $86.6 million Series B financing Internationally recognized oncologist and physician-scientist Aleix Prat, MD, PhD, appointed Chief Medical Officer, as Jutta Amersdorffer, MD, MBA, […]